Comprehensive genomic profiling identifies a subset of Crizotinib- responsive ALK-rearranged non-small cell lung cancer not detected by fluorescence in situ hybridization

Oncologist

Volumn 21, Issue 6, 2016, Pages 762-770

  Ali, Siraj M ^a   Hensing, Thomas ^b,c   Schrock, Alexa B ^a   Allen, Justin ^a   Sanford, Eric ^a   Gowen, Kyle ^a   Kulkarni, Atul ^d   He, Jie ^a   Suh, James H ^a   Lipson, Doron ^a   Elvin, Julia A ^a   Yelensky, Roman ^a   Chalmers, Zachary ^a   Chmielecki, Juliann ^a   Peled, Nir ^e   Klempner, Samuel J ^f   Firozvi, Kashif ^g   Frampton, Garrett M ^a   Molina, Julian R ^h   Amenon, Smith ⁱ   Brahmer, Julie R ^j   MacMahon, Heber ^c   Nowak, Jan ^b   Ignatius Ou, Sai Hong ^f   Zauderer, Marjorie ^k   Ladanyi, Marc ^k   Zakowski, Maureen ^k   Fischbach, Neil ^l   Ross, Jeffrey S ^a,m   Stephens, Phil J ^a   Miller, Vincent A ^a   Wakelee, Heather ⁿ   Ganesan, Shridar ^d   Salgia, Ravi ^c   more..

^a FOUNDATION MEDICINE   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^e Davidoff Cancer Center   (Israel)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g Maryland Hematology Oncology   (United States)

^h MAYO CLINIC   (United States)

ⁱ Froedtert Hospital   (United States)

^j JOHNS HOPKINS UNIVERSITY   (United States)

^k MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^l Bridgeport Oncology   (United States)

^m ALBANY MEDICAL COLLEGE   (United States)

ⁿ STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

ALK; Crizotinib; Fluorescence in situ hybridization; Fusion; Genomic profiling

Indexed keywords

ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MUCIN; PACLITAXEL; PEMETREXED; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CASE REPORT; COLONY FORMATION; COPY NUMBER VARIATION; DNA EXTRACTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHADENOPATHY; NON SMALL CELL LUNG CANCER; PLEURA BIOPSY; PLEURA EFFUSION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TRANSIENT TRANSFECTION; WESTERN BLOTTING; CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; GENETICS; GENOMICS; LUNG NEOPLASMS; MALE; PROCEDURES;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION PROFILING; GENE REARRANGEMENT; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84975257905     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0497     Document Type: Article

References (19)

1. Shaw AT, Hsu PP, Awad MM et al. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013;13:772-787.
2. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol 2013;31:1097-1104.
3. US Food and Drug Administration. List of cleared or approved companion diagnostic devices (in vitro and imaging tools). Available at http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm. Accessed August 22, 2015.
4. Heuckmann JM, Balke-Want H, Malchers F et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012;18:4682-4690.
5. Shaw AT, Kim D-W, Nakagawa K et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-2394.
6. Shaw AT, Kim D-W, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-1197.
7. Solomon BJ, Mok T, Kim D-W et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 2014;371:2167-2177.
8. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31:1023-1031.
9. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol 2015;16:e342-e351.
10. Thomas A, Liu SV, Subramaniam DS et al. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat Rev Clin Oncol 2015;12:511-526.
11. Drilon A, Wang L, Arcila ME et al. Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “drivernegative” lung adenocarcinomas. Clin Cancer Res 2015;21:3631-3639.
12. Pirazzoli V, Nebhan C, Song X et al. Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1. Cell Reports 2014;7:999-1008.
13. Lipson D, Capelletti M, Yelensky R et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012;18:382-384.
14. Ou S-HI, Klempner SJ, Greenbowe JR et al. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALKrearranged NSCLC patients with resistance to Alectinib. J Thorac Oncol 2014;9:1821-1825.
15. Hong M, Kim RN, Song J-Y et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol 2014;9:419-422.
16. Fang DD, Zhang B, Gu Q et al. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib. J Thorac Oncol 2014;9:285-294.
17. Office of Public Health Strategy and Analysis, US Food and Drug Administration. The public health evidence for FDA oversight of laboratory developed tests. 20 case studies - UCM472777.pdf. Available at http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/UCM472777.pdf. Accessed November 29, 2015.
18. Murphy K, Topel R. The value of health and longevity. J Polit Econ 2006;114:871-904
19. National Comprehensive Cancer Network. Lung cancer screening, v.2.2016. Available at https://www.nccn.org/professionals/physician_gls/recently_updated.asp